海思科：创新药HSK44459片新增适应症临床试验获批准

Core Viewpoint - The company Haishi Ke (002653) has received approval from the National Medical Products Administration for clinical trials of its drug HSK44459 for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease [1] Group 1 - The National Medical Products Administration issued a "Clinical Trial Approval Notification" for HSK44459, indicating that the application for the new indication meets the requirements for drug registration [1] - Haishi Ke's subsidiary, Shanghai Haishi Shengnuo Pharmaceutical Technology Co., Ltd., has also received a "Acceptance Notification" for its clinical trial applications for HSK50042 and HSK55879 [1]